Fresenius shares showed minimal movement on Tuesday, edging up just 0.07% to €41.52 in XETRA trading, as investors reacted cautiously to the company’s new biosimilar partnership. Its Kabi division announced a licensing agreement with a Polish biotech firm for PB016, a biosimilar candidate mimicking Takeda’s Entyvio, used to treat inflammatory bowel diseases like Crohn’s. The Polish partner will handle development and manufacturing, while Fresenius secures exclusive global marketing rights outside the Middle East and North Africa. The deal aligns with Kabi’s strategy to expand its biosimilar portfolio for autoimmune and oncology treatments, though commercialization remains years away due to lengthy clinical trials.
Market Skepticism Persists
Meanwhile, Fresenius’s dialysis-focused sibling, FMC, faced a 7% stock plunge after missing Q2 earnings expectations by €16 million, despite cost-cutting progress. Stagnant treatment volumes in the U.S.—a key market—offset gains elsewhere, underscoring persistent challenges. While Fresenius Kabi’s biosimilar push offers long-term potential, near-term investor sentiment remains muted amid broader sector headwinds.
Ad
Fresenius Stock: Buy or Sell?! New Fresenius Analysis from November 7 delivers the answer:
The latest Fresenius figures speak for themselves: Urgent action needed for Fresenius investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 7.
Fresenius: Buy or sell? Read more here...
